NCT04037254 2026-03-16
Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring
NRG Oncology
Phase 1/2 Completed
NRG Oncology
Emory University
University of Utah
Radiation Therapy Oncology Group
Wake Forest University Health Sciences
OHSU Knight Cancer Institute
Radiation Therapy Oncology Group
Radiation Therapy Oncology Group
University of California, San Francisco
Mayo Clinic
University of Kentucky
Radiation Therapy Oncology Group
Proton Collaborative Group